1. "Craig Moskowitz"
  2. "Andrew Zelenetz"
  3. "Joachim Yahalom"
Formats
  1. Meeting Abstract (32)
  2. Journal Article (30)
Groups
  1. Center for Hematologic Malignancies (62)
  2. Department of Medicine (62)
  3. Hematologic Malignancies, Division of (62)
  4. Lymphoma (62)
  5. Radiation Oncology, Department of (62)
  6. Survivorship Research (62)

More Groups

People
  1. Andrew Zelenetz (62)
  2. Craig Moskowitz (62)
  3. Joachim Yahalom (62)
  4. David Straus (36)
  5. Carol Portlock (34)
  6. Ariela Noy (32)

More People

Years
  1. 2023 (1)
  2. 2021 (2)
  3. 2020 (2)
  4. 2018 (1)
  5. 2017 (4)
  6. 2016 (3)

More Years

Publications
  1. Blood (33)
  2. British Journal of Haematology (6)
  3. Journal of Clinical Oncology (6)
  4. Annals of Oncology (3)
  5. Bone Marrow Transplantation (3)
  6. Haematologica (2)

More Publications

Publishers
  1. American Society of Hematology (34)
  2. American Society of Clinical Oncology (6)
  3. John Wiley & Sons (6)
  4. Elsevier Inc. (3)
  5. Nature Publishing Group (3)
  6. Oxford University Press (3)

More Publishers

Results (62)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes of patients with positive interim positron emission tomography (PET) continuing ABVD in the clinical setting
    Journal Article

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S.; Kumar, A.; Matasar, M. J.; more...
    Cancers (2023)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schöder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save
  • Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients
    Journal Article

    Yahalom, J.; Xu, A. J.; Noy, A.; Lobaugh, S.; Chelius, M.; Chau, K.; Portlock, C.; Hajj, C.; Imber, B. S.; Straus, D. J.; more...
    Blood Advances (2021)

    Fulltext@MSK | Save
  • Impact of interim PET on Hodgkin lymphoma treatment outcome and survival in clinical practice
    Meeting Abstract

    Zheng, S.; Gupta, K.; Goyal, P.; Nakajima, R.; Michaud, L.; Batlevi, C. L.; Hamlin, P. A.; Horwitz, S. M.; Kumar, A.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Early data from a phase II trial investigating the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S. A.; Ames, A.; Biggar, E.; Moskowitz, A. J.; Batlevi, C. L.; Caron, P.; Hamilton, A. M.; Moskowitz, C. H.; Matasar, M. J.; more...
    Journal of Clinical Oncology (2020)

    Fulltext@MSK | Save
  • Outcomes of relapsed and refractory primary mediastinal (thymic) large B cell lymphoma treated with second-line therapy and intent to transplant
    Journal Article

    Vardhana, S.; Hamlin, P. A.; Yang, J.; Zelenetz, A.; Sauter, C. S.; Matasar, M. J.; Ni, A.; Yahalom, J.; Moskowitz, C. H.
    Biology of Blood and Marrow Transplantation (2018)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R. H.; Budde, L.; Barr, P. M.; Batlevi, C. L.; Caron, P.; Chen, R. W.; Constine, L. S.; Courtien, A.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • Prognostic significance of baseline metabolic tumor volume in relapsed and refractory Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Cadzin, B. R.; Fox, S. Y.; Gerecitano, J.; more...
    Blood (2017)

    Fulltext@MSK | Save
  • A pilot study of brentuximab vedotin and AVD chemotherapy followed by 20 Gy involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma
    Meeting Abstract

    Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P. M.; Batlevi, C. L.; Chen, R.; Constine, L. S.; Courtien, A. I.; Dandapani, S. V.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save
  • Baseline metabolic tumor volume is an independent prognostic factor for relapsed and refractory Hodgkin lymphoma patients receiving PET-adapted salvage therapy with brentuximab vedotin and augmented ICE
    Meeting Abstract

    Moskowitz, A. J.; Schöder, H.; Gavane, S.; Thoren, K. L.; Fleisher, M.; Yahalom, J.; McCall, S. J.; Fox, S. Y.; Gerecitano, J.; Grewal, R.; more...
    Hematological Oncology (2017)

    Fulltext@MSK | Save